NORTH BRUNSWICK, N.J.--(BUSINESS WIRE)--Advaxis, Inc., (OTCBB: ADXS), the live, attenuated Listeria monocytogenes (Listeria) immunotherapy company was awarded a Qualifying Therapeutic Discovery Project (QTDP) credit from the Federal Government for ADXS11-001, the Company’s lead immunotherapeutic construct totaling $244,479.